Novel De Novo Mutations in KIF1A as a Cause of Hereditary Spastic Paraplegia With Progressive Central Nervous System Involvement

Leslie Hotchkiss, BS1,2, Sandra Donkervoort, MS, CGC1, Meganne E. Leach, CRNP1,3, Payam Mohassel, MD1, Diana X. Bharucha-Goebel, MD1,3, Nathaniel Bradley, BS1, David Nguyen, BS1, Ying Hu, MS1, Juliana Gurgel-Giannetti, MD, PhD4, and Carsten G. Bönnemann, MD1

Abstract
Hereditary spastic paraplegias are a clinically and genetically heterogeneous group of disorders characterized by lower extremity spasticity and weakness. Recently, the first de novo mutations in KIF1A were identified in patients with an early-onset severe form of complicated hereditary spastic paraplegia. We report two additional patients with novel de novo mutations in KIF1A, hereby expanding the genetic spectrum of KIF1A-related hereditary spastic paraplegia. Both children presented with spastic paraplegia and additional findings of optic nerve atrophy, structural brain abnormalities, peripheral neuropathy, cognitive/language impairment, and never achieved ambulation. In particular, we highlight the progressive nature of cerebellar involvement as captured on sequential magnetic resonance images (MRIs), thus linking the neurodegenerative and spastic paraplegia phenotypes. Exome sequencing in patient 1 and patient 2 identified novel heterozygous missense mutations in KIF1A at c.902G>A (p.R307Q) and c.595G>A (p.G199 R), respectively. Therefore, our report contributes to expanding the genotypic and phenotypic spectrum of hereditary spastic paraplegia caused by mutations in KIF1A.

Keywords
hereditary spastic paraplegia, neuromuscular disorders, KIF1A, genetics

Received August 11, 2015. Received revised January 21, 2016. Accepted for publication February 3, 2016.

Hereditary spastic paraplegias are a clinically and genetically heterogeneous group of disorders characterized by lower extremity spasticity and weakness, with onset ranging from early childhood through late adulthood. Complicated hereditary spastic paraplegias exhibit additional clinical features, including cognitive impairment, ataxia, optic nerve atrophy, retinopathy, dementia, peripheral neuropathy, or epilepsy.1 Hereditary spastic paraplegias can be inherited in an autosomal dominant (AD), autosomal recessive (AR), or X-linked recessive manner. The pathophysiology of hereditary spastic paraplegia involves a length-dependent, progressive, distal axonopathy and retrograde degeneration of the corticospinal tracts.1 This degeneration results from alterations in various neuronal cellular mechanisms including neuronal development, protein folding, endoplasmic reticulum membrane formation and shaping, mitochondrial function and maintenance, lysosomal and endosomal function, myelination, DNA repair, lipid metabolism, and axonal transport.1 To date, 55 hereditary spastic paraplegia–causing genes have been identified in these functional areas and new gene discoveries are rapidly emerging.1

One recently discovered hereditary spastic paraplegia–associated gene, KIF1A (2q37.3), encodes for Kinesin-like protein KIF1A (KIF1A), which is involved in neuron-specific axonal

1 National Institutes of Health, Bethesda, MD, USA
2 Weill Cornell Medical College, New York, NY, USA
3 Children’s National Medical Center, Washington, DC, USA
4 Universidade Federal de Minas Gerais, Belo Horizonte—MG, Brazil

Corresponding Author:
Carsten G. Bönemann, MD, Neuromuscular and Neurogenetic Disorders of Childhood Section, Neurogenetics Branch, National Institute of Neurological Disorder and Stroke, National Institutes of Health, Bldg 35 Porter NRC, Room 2A-116, 35 Covent Drive MSC 3705, Bethesda, MD 20892, USA.
Email: carsten.bonnemann@nih.gov
transport. Although recessive \textit{KIF1A} mutations are known to cause a rare form of childhood-onset pure hereditary spastic paraplegia, heterozygous de novo mutations in \textit{KIF1A} were recently identified as the cause of a more severe phenotype of dominant, early-onset, complicated hereditary spastic paraplegia characterized by cognitive impairment, spastic paraplegia, optic nerve atrophy, peripheral neuropathy, cerebellar atrophy, and seizures.\textsuperscript{2,3,4} Here we report two additional patients with novel, de novo dominant, missense mutations in \textit{KIF1A}, hereby providing further confirmation of de novo dominant mutations causing this new phenotype of complicated hereditary spastic paraplegia.

\section*{Materials and Methods}

Patients were evaluated under protocol 12-N-0095 approved by the National Institute of Neurological Disease and Stroke institutional review board at the National Institutes of Health (NIH). Informed consent was obtained from the family by a qualified investigator. Whole exome sequencing was performed at the NIH Intramural Sequencing Center using Illumina’s TruSeq Exome Enrichment Kit and Illumina HiSeq 2000 sequencing instruments. Results were confirmed with Sanger sequencing on an ABI 3130x1 capillary sequencer, in forward and reverse direction. Segregation was performed on the parents of both patients. Mutations were analyzed using GEM.app, x-browse, and PolyPhen-2 and searched for in dbSNP, NHLBI EVS, and Exac Browser. Exome sequencing data were processed through a pipeline based on Picard, using base quality score recalibration and local realignment at known indels. We used the BWA aligner for mapping reads to the human genome build 37 (hg19). Single-nucleotide polymorphisms and insertions/deletions (indels) were jointly called across all samples using Genome Analysis Toolkit HaplotypeCaller package version 3.1. Default filters were applied to single-nucleotide polymorphism and indel calls using the Genome Analysis Toolkit Variant Quality Score Recalibration approach. Lastly, the variants were annotated using Variant Effect Predictor. Clinical magnetic resonance images (MRIs) and reports were also obtained with informed consent.

\section*{Clinical Presentation}

\textbf{Patient 1}

Patient 1, who was initially evaluated at age 14 years, is a young man from Saudi Arabia with cognitive impairment, progressive cerebellar atrophy, optic nerve atrophy, peripheral neuropathy, seizures, and a combination of lower extremity spasticity and upper extremity hypotonia. First concerns arose at age 6 months when he was unable to roll over and had poor head control. He was then diagnosed with optic nerve hypoplasia at 10 months, and visual evoked potentials at 1 year of age were consistent with optic nerve atrophy. He was able to stand with support by 2.5 years of age, but lost this ability by age 11. His language development was delayed so that he only spoke a few words. By follow-up report, he developed generalized tonic-clonic seizures at 15 years of age. On examination, he had distal wasting with small hands and feet. He had increased tone and spasticity in the lower extremities with extensor plantar responses bilaterally, but was hypotonic and areflexic in the upper extremities. His strength appeared grossly normal. Additionally, he had scoliosis, distal joint hyperlaxity, and multiple joint contractures.

Sequential MRIs show an initially normal cerebellum, with development of atrophy with time and a persistent thin corpus callosum (Figure 1). Family history is significant for consanguinity in the parents and a deceased sister with congenital muscular dystrophy due to a homozygous pathogenic mutation in exon 4 of \textit{FKRP}. Patient 1 is a heterozygous carrier for the \textit{FKRP} mutation and muscle biopsy at 5 years of age was normal.

\textbf{Patient 2}

Patient 2 is a 6-year-old boy from Brazil with cognitive impairment, cerebellar atrophy, optic nerve atrophy, distal neuropathy, spastic paraplegia, and axial hypotonia. He was born with bilateral clubfoot deformities. At 6 months of age, he was unable to roll over or sit and had poor head control. At 1 year of age, he was diagnosed with optic nerve atrophy. His language development was delayed and he had acquired about 20 words by 6 years of age. He made slow gains in cognitive function and had shown no regression or loss of functions previously obtained. On examination, he was unable to follow commands and had minimal speech. He had truncal hypotonia and a spastic increase in tone, more prominent in the lower extremities (Figure 2). He rolled from supine to prone to push himself into a sitting position, but could not stand or walk. Reflexes were hyperactive. His strength was within normal limits for his age, except for some apparent weakness in his hands. He had mild kyphosis and contractures in the ankles with persistent clubfoot deformities.

Muscle ultrasound showed a mixed pattern of increased echogenicity in a streak like pattern and fasciculations were seen in various muscles, further confirming a neurogenic etiology of the changes. The hands and distal lower extremity muscles were most involved. Brain MRI showed a thinning of the corpus callosum and cerebellar atrophy that developed over time (Figure 1).

\section*{Genetic Results}

Exome sequencing in patients 1 and 2 identified novel heterozygous missense mutations in \textit{KIF1A} at c.902G>A (p.R307Q) and c.595G>A (p.G199 R), respectively. Parental segregation was negative, indicating that the mutations occurred de novo. These mutations were not reported in dbSNP, NHLBI EVS, and Exac Browser databases. Both mutations were designated as disease-causing in x-browse and were predicted to be probably damaging with a Polyphen2 score of 1.000. No other pathogenic mutations in known hereditary spastic paraplegia genes were identified.

\section*{Discussion}

Here we report two novel de novo \textit{KIF1A} mutations in patients presenting with early-onset complicated hereditary spastic paraplegia characterized by spastic paraplegia and additional findings: (1) cognitive impairment, (2) nonambulation, (3) language impairment, (4) optic nerve atrophy, (5) peripheral neuropathy, and (6) progressive cerebellar atrophy. Additionally, patient 1 developed seizures as a teenager. This phenotype is consistent with the previously reported de novo \textit{KIF1A} mutations (Table 1), with our patients representing an earlier onset and more severe end of the clinical spectrum compared to the
pure hereditary spastic paraplegia caused by recessive mutations in KIF1A.

In our patients, serial MRIs showed progressive cerebellar atrophy over a few years without overt clinical manifestations. Importantly, MRIs in the first year of life revealed appropriately sized cerebellums. Although the clinical course so far has appeared relatively static from a motor perspective, patient 1 developed seizures at 15 years of age, similarly to previously reported de novo patients. A recent report of de novo KIF1A mutations causing progressive encephalopathy and brain atrophy in six patients illustrates the central nervous system involvement associated with this new phenotype (Table 1). Our patients firmly link the progressive and degenerative nature of brain involvement with the spastic paraplegia that is characteristic of hereditary spastic paraplegia.

KIF1A is a kinesin (KIFs) that participates in axonal anterograde transport of synaptic vesicles. Though initially thought to act as a monomer, recent studies show it primarily acts as a highly processive dimer.4,5 KIF1A uses ATP hydrolysis to power its movement along microtubules. ATP hydrolysis produces conformational changes in 3 regions of the motor domain (amino acids [aa] 1-361): switch I region (aa...
202-218), switch II cluster (aa 248-324), and the neck-linker region (aa 353-361). The 4 mutations in the initial report of recessive KIF1A and 11 recently reported de novo missense mutations all fall in the motor domain and many are in the regions that undergo conformational change (Figure 3).2,3,7 Similarly, both patients presented here were found to have missense mutations in the motor domain of KIF1A (Figure 3).2

Patient 1’s p.R307Q substitution falls within 1 of the 3 microtubule-binding domains (Figure 3). This domain’s primary actor is the K-loop (aa 286-300), a unique feature of the KIF1 family. The high affinity of the K-loop for the microtubule is thought to contribute to KIF1A’s high processivity.8 This interaction is likely mediated by the strong positive charge of the K-loop (lysine rich) and the negative charge of tubulin (glutamate rich).8 Okada and Hirokawa showed that a reduction in the K-loop’s positive charge decreased its affinity for microtubules and subsequently decreased KIF1A’s processivity.8 Patient 1’s mutation substitutes a positively charged arginine for an uncharged glutamine. This reduction in positive charge near the K-loop may therefore weaken KIF1A’s binding to microtubules.

Table 1. Clinical findings of Patients 1 and 2, as well as a summary of clinical findings in the two previous reports of patients with de novo dominant KIF1A mutations.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>KIF1A mutation (de novo)</td>
<td>c.902G&gt;A</td>
<td>c.595G&gt;A</td>
<td>Various de novo missense mutations</td>
<td>Various de novo missense mutations</td>
</tr>
<tr>
<td>Gender</td>
<td>Male</td>
<td>Male</td>
<td>9 female, 5 male</td>
<td>4 female, 2 male</td>
</tr>
<tr>
<td>Age (y)</td>
<td>14</td>
<td>6</td>
<td>2-24</td>
<td>1.5-16</td>
</tr>
<tr>
<td>Age of onset and initial findings</td>
<td>6 mo: delayed milestones (head control, rolling over)</td>
<td>Congenital: bilateral clubfoot</td>
<td>3/14 congenital</td>
<td>3/14 young childhood</td>
</tr>
<tr>
<td>Cognition</td>
<td>Severe cognitive impairment with language delay</td>
<td>Severe cognitive impairment with language delay</td>
<td>4/14 mild ID</td>
<td>6/6 severe global developmental delay</td>
</tr>
<tr>
<td>Language development</td>
<td>Words and simple sentences</td>
<td>Approximately 20 words</td>
<td>3/14 normal</td>
<td>4/6 severe language delay</td>
</tr>
<tr>
<td>Maximum motor function</td>
<td>Get to seated (at 5 y old)</td>
<td>Sit when placed (at 2.5 y old)</td>
<td>6/14 independent ambulation</td>
<td>2/6 ambulatory with assistance</td>
</tr>
<tr>
<td>Ophthalmologic involvement</td>
<td>Sluggish pupillary responses, does not track, roving eye movements, conjugate gaze, pale optic disks</td>
<td>Sluggish pupillary responses, fixates on light, does not track, minimal nystagmus, pale optic disks</td>
<td>3/14/14 optic nerve atrophy</td>
<td>3/6 optic nerve atrophy</td>
</tr>
<tr>
<td>Microcephaly</td>
<td>Yes, 50.5 cm (&lt;3rd percentile)</td>
<td>No, 50 cm (25th percentile)</td>
<td>4/14 yes</td>
<td>4/6 yes</td>
</tr>
<tr>
<td>Epilepsy</td>
<td>Yes, onset at 15 y old, generalized tonic-clonic</td>
<td>No</td>
<td>3/14 epilepsy</td>
<td>2/6 seizures</td>
</tr>
<tr>
<td>EMG/NCS</td>
<td>Distal motor neuropathy with absent sensory responses in upper and lower extremities</td>
<td>Axonal sensory-motor polyneuropathy</td>
<td>4/14 neuropathy</td>
<td>4/6 no seizures</td>
</tr>
<tr>
<td>Spine</td>
<td>Scoliosis: T11-L4 &amp; T5-T11</td>
<td>Minor kyphosis on exam</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Contractures</td>
<td>Elbows (end-grade, wrists, ankles, knees (almost 90°)</td>
<td>Ankle (Achilles tendon release at age 6 mo)</td>
<td>NR</td>
<td>NR</td>
</tr>
</tbody>
</table>

Abbreviations: EEG, electroencephalogram; EMG, electromyogram; ID, intellectual disability; NR, not reported; NCS, nerve conduction studies.
Figure 3. (A) Schematic representation of KIF1A. The motor domain (aa 1-361) is detailed on the left with pathogenic mutations identified. Mutations highlighted in green are the early reported homozygous mutations. Those in blue are the recently reported de novo mutations. The mutations in purple are those of patients 1 and 2 reported here. Additionally, the microtubule-binding domains (MT1, MT2, MT3) are labeled. The schematic also includes distal mutations, not in the motor domain, that have been reported to cause Hereditary Sensory and Autonomic Neuropathy IIC (HSAN2C). Other important functional domains are identified: forkhead-associated domain (FHA) and pleckstrin homology domain (PH). (B) Illustration of the amino acid conservation among KIF1A orthologs at the residues altered in the 2 cases reported (G199 and R307, highlighted in purple). The amino acid alignment was generated using HomoloGene (NCBI) and includes human (Homo sapiens; NP_001022041.2), mouse (Mus musculus; NP_032466.2), chicken (Gallus gallus; XP_003641781.1), Zebrafish (Danio rerio; XP_005166002.1), Drosophila (Drosophila melanogaster; NP_001246373.1), roundworm (Caenorhabditis elegans; NP_001022041.1), and frog (Xenopus tropicalis; XP_002933830.2). (The color version of this figure is available in the online version at http://jcn.sagepub.com/.)

Patient 2’s G199R substitution involves the first amino acid in the loop L9, a secondary structure in the switch I region. L9 performs a β-to-α conformational change that allows for γ-phosphate to be released after ATP hydrolysis. This substitution in L9 may impact the successful turnover of ATP hydrolysis, which is crucial for KIF1A function. Additionally, Lee et al describe a patient with a mutation at A202 (also in the L9 loop) who presents with a similar phenotype. Furthermore, anterograde movement of KIF1A is impaired in A202P mutant mice as demonstrated by only a 9.9% accumulation of KIF1A in the distal neurite compared with 93.2% in the wild type. Because patient 2’s mutation affects a residue that is only 3 amino acids away, is part of the same secondary structure, and results in a similar phenotype, it is likely that p.G199R has a similar disease-causing effect.

Given KIF1A’s functional requirements for efficient ATP hydrolysis, mutations in the regions involved in conformational change and microtubule binding are most likely to be disease causing. However, functional studies in cellular and animal models would be the next step to further support this assumption. Recent studies suggest that KIF1A is important in the transport of dense core vesicles carrying precursor proteins bound for the synapse. The transport of these vesicles, often over long distances, is crucial for neuronal development, survival, learning, and memory. The impairment of these functions likely contributes to the characteristic selective susceptibility and degeneration of long axons in hereditary spastic paraplegia.

Our patients, and other reports of dominantly acting KIF1A mutations, suggest a more severe phenotype than recessively inherited KIF1A mutations. A recent study of microtubule gliding assays showed a decreased velocity of KIF1A with de novo mutations compared with recessive, consistent with the observed phenotypic variability. One possible explanation for this is a dominant negative effect, especially given KIF1A’s potential homodimerization in vivo. Additionally, the previously reported recessive mutations were all missense mutations, leaving the possibility that null mutations may be embryonically lethal. However, a recent report of a de novo KIF1A mutation resulting in pure hereditary spastic paraplegia in a father and then his son also illustrates the still evolving phenotypic variability of KIF1A mutations. Along the same lines, more severe recessive KIF1A mutations causing complicated hereditary spastic paraplegia or mild dominantly acting mutations may be discovered in the future. Therefore, these 2 case studies contribute to our expanding knowledge of genotype-phenotype correlations in hereditary spastic paraplegia.

Author Contributions
LH was the primary creator and author of this manuscript. SD interpreted the exome results, identified the mutations as causative, provided guidance throughout the writing and editing process. MEL and DXBG were involved in the clinical evaluation of patients and the editing of the manuscript. PM assisted with the brain magnetic resonance imaging (MRI) interpretation and editing. NB, BN, and YH were responsible for confirmation of the exome results, identified the mutations as causative, provided guidance and editorial support throughout the drafting of this manuscript.

Declaration of Conflicting Interests
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: All funding was provided by NIH.

Ethical Approval
The study of these patients, under protocol 12-N-0095 (IRB approval number), was approved by the National Institute of Neurological Disease and Stroke Internal Review Board at the National Institutes of Health (NIH).

References